Pliant Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Pliant Therapeutics generated cash of -$116,361,000, which is less than the previous year. Cash used in financing activities reached the amount of $274,405,000 last year. Net change in cash is therefore $31,032,000.
Cash Flow
| 2017 | -16.92M | -1.40M | 20.00M |
|---|---|---|---|
| 2018 | -28.32M | -2.32M | 87.34M |
| 2019 | -2.75M | -17.93M | 45.53M |
| 2020 | -37.27M | -210.86M | 213.21M |
| 2021 | -75.44M | 73.69M | 2.52M |
| 2022 | -94.63M | -150.20M | 226.85M |
| 2023 | -116.36M | -127.01M | 274.40M |
PLRX Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 33.68M | 51.66M | 50.88M | 85.80M | 60.94M | 4.25M | 2.57M |
Operating activities | |||||||
Net income | -161.33M | -123.32M | -97.26M | -41.53M | -631K | -30.27M | -18.33M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 1.84M | 1.82M | 1.53M | 1.31M | 1.11M | 666K | 292K |
Stock-based compensation expense | 44.48M | 22.59M | 10.43M | 3.89M | 1.82M | 0 | 33K |
| Deferred income tax benefit | 44.48M | 22.59M | 10.43M | 3.89M | 1.82M | 0 | 33K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 1.98M | 15K | 7.28M | -2.22M | -7.05M | 0 | 0 |
Inventories | 0 | 0 | 0 | 113K | 3.19M | 0 | 0 |
Accounts payable | 2.96M | -1.35M | 891K | 922K | -1.25M | 760K | 0 |
Cash generated by operating activities | -116.36M | -94.63M | -75.44M | -37.27M | -2.75M | -28.32M | -16.92M |
Investing activities | |||||||
Purchases Of Investments | -583.06M | -325.71M | -219.88M | -322.60M | -51.96M | 0 | 0 |
Investments In Property Plant And Equipment | -921K | -1.76M | -1.95M | -1.53M | -964K | -2.32M | -1.40M |
Acquisitions Net | 0 | 148.44M | -75.65M | 209.33M | 254K | 0 | 0 |
Cash generated by investing activities | -127.01M | -150.20M | 73.69M | -210.86M | -17.93M | -2.32M | -1.40M |
Financing activities | |||||||
Common Stock Issued | 275.25M | 217.56M | 2.98M | 160.75M | 174K | 32K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | -12K |
Repayments of term debt | 0 | 10M | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 274.40M | 226.85M | 2.52M | 213.21M | 45.53M | 87.34M | 20.00M |
Net Change In Cash | 31.03M | -17.98M | 783K | -34.92M | 24.85M | 56.69M | 1.67M |
Cash at end of period | 64.71M | 33.68M | 51.66M | 50.88M | 85.80M | 60.94M | 4.25M |
| Data source | Data source | Data source | Data source |